Pathstone Holdings
CGTX icon

Pathstone Holdings’s Cognition Therapeutics CGTX Stock Holding History

Pathstone Holdings’s Portfolio CGTX Stock Details CGTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-2,205,377
Closed -$4.08M – 2304
2023
Q4 		$4.08M Buy
+2,205,377
New +$2.92M 0.02% 483

Other funds holding CGTX

ACM
AIGH Capital Management Baltimore, Maryland $733M AUM 327.32% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
AIC
AWM Investment Company New York $903M AUM 163.47% 1-Year Est. Return
Alyeska Investment Group
Alyeska Investment Group Chicago, Illinois $35.4B AUM 33.54% 1-Year Est. Return
TIM
Timelo Investment Management Aurora, Ontario, Canada $127M AUM 23.73% 1-Year Est. Return
CCM
Corsair Capital Management New York $673M AUM 109.99% 1-Year Est. Return
HWM
Hohimer Wealth Management Seattle, Washington $847M AUM 29.89% 1-Year Est. Return
CC
Carlson Capital Dallas, Texas $318M AUM 27.64% 1-Year Est. Return
AFG
American Financial Group Cincinnati, Ohio $270M AUM 3.25% 1-Year Est. Return
KAS
Kestra Advisory Services Austin, Texas $26.4B AUM 21.05% 1-Year Est. Return

Pathstone Holdings's CGTX Position: Q1 2024 in Review

Pathstone Holdings sold out of Cognition Therapeutics (CGTX) in Q1 2024, closing a stake of 2,205,377 shares — an estimated $4.08M sold.

Pathstone Holdings first reported a position in CGTX in Q4 2023 and held it in 1 quarter. The position peaked at $4.08M in Q4 2023. 47 funds tracked by Wall St. Rank hold CGTX as of Q1 2024.

  • Pathstone Holdings reported no remaining Cognition Therapeutics position as of Q1 2024 after selling out during the quarter.
  • Pathstone Holdings sold 2,205,377 Cognition Therapeutics shares in Q1 2024, an estimated $4.08M.
  • Pathstone Holdings first reported a position in Cognition Therapeutics in Q4 2023 and held it in 1 quarter.
  • Pathstone Holdings's Cognition Therapeutics position peaked at $4.08M in Q4 2023.
  • 47 funds tracked by Wall St. Rank held Cognition Therapeutics as of Q1 2024.

Based on Pathstone Holdings's 13F filing for Q1 2024, filed 13 May 2024.